Low TFAP2B transcript levels are associated with unfavorable prognostic markers and poor outcome in neuroblastoma.
TFAP2B may be silenced by promoter methylation in unfavorable neuroblastoma.
TFAP2B plays a role in neuronal differentiation of neuroblastoma cells.